Zimmer Biomet Reports Strong Q4 & Full-Year 2025 Results, Issues 2026 Guidance, and Authorizes $1.5B Share Repurchase

summarizeSummary

Zimmer Biomet announced its Q4 and full-year 2025 financial results, reporting strong sales growth and adjusted EPS increases, alongside providing 2026 guidance and authorizing a new $1.5 billion share repurchase program.

check_boxKey Events

• Strong Q4 and Full-Year 2025 Financial Performance

  The company reported fourth quarter net sales of $2.244 billion, an increase of 10.9% reported and 5.4% on an organic constant currency basis. Full-year net sales reached $8.232 billion, up 7.2% reported and 3.9% organic constant currency. Adjusted diluted EPS for Q4 was $2.42 (up 4.8%) and for the full year was $8.20 (up 2.5%).

• New $1.5 Billion Share Repurchase Authorization

  Zimmer Biomet's Board of Directors approved a new stock repurchase authorization, allowing the company to repurchase up to $1.5 billion in common stock, effective February 9, 2026, with no expiration date. This follows $250 million in repurchases during Q4 2025.

• Full-Year 2026 Financial Guidance Provided

  The company projects 2026 reported revenue change of 2.5% - 4.5% and organic constant currency revenue change of 1.0% - 3.0%. Adjusted diluted EPS for 2026 is guided to be between $8.30 and $8.45.

• Strategic Sales Organization Transition

  Management noted that the transition to a predominantly direct and specialized sales organization in the U.S. will temper 2026 sales guidance but is expected to drive durable long-term growth and solidify market leadership.

auto_awesomeAnalysis

Zimmer Biomet Holdings, Inc. reported solid financial results for the fourth quarter and full-year 2025, meeting its initial revenue growth, EPS, and free cash flow commitments. The company demonstrated meaningful revenue acceleration in Q4, driven by new product innovation. Looking ahead, the company provided full-year 2026 financial guidance, which includes tempered sales growth expectations due to a strategic transition to a predominantly direct and specialized sales organization in the U.S. Despite this, management expressed confidence that this move will drive durable long-term growth. The authorization of a new $1.5 billion stock repurchase program signals a strong commitment to returning capital to shareholders and minimizing dilution, which is a significant positive for investors.